STOCK TITAN

Veradigm Stock Price, News & Analysis

MDRX OTC

Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.

Veradigm Inc. (MDRX) is a healthcare technology company that focuses on healthcare data and technology solutions for providers, payers, and biopharma organizations. News about Veradigm often centers on how the company uses its platforms, data, connectivity, and expertise within the Veradigm Network to support clinical, operational, and financial performance in healthcare.

Investors and industry observers following MDRX news can expect updates on business performance, financing, and capital structure, as reflected in Veradigm’s announcements about financial outlooks, cash and debt levels, and debt financing arrangements. The company also issues news about its progress on financial reporting, including the filing of its Annual Report on Form 10-K with restated financial statements and its efforts to become current in SEC filings and pursue relisting on a national stock exchange.

Operational and client-focused news includes case studies and collaborations that highlight Veradigm’s role in value-based care, payer–provider integration, and revenue cycle management. Examples include recognition through a KLAS Points of Light Award for delivering insights at the point of care and announcements about organizations selecting Veradigm Revenue Cycle Services, Coding Services, and related offerings such as Veradigm Revenue Analytics, Veradigm Practice Management, and Veradigm Payerpath.

Veradigm also issues news on product and capability developments, such as applying artificial intelligence to deidentified EHR data to generate real-world evidence for GLP-1 therapies, and on thought leadership initiatives like the Smart Medicine Podcast. Governance and corporate updates, including leadership appointments and amendments to the company’s stockholder rights plan, are additional recurring themes. For a comprehensive view of MDRX-related developments, this news page aggregates these announcements and related coverage in one place.

Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) announced an enhanced strategic collaboration with Insiteflow to expand Veradigm Payer Insights (VPI) beyond its current EHR footprint. The partnership extends VPI to additional EHR platforms, including Epic, enabling real-time delivery of payer insights directly into healthcare provider workflows.

The collaboration, which began in 2022, integrates care gaps alerts and patient condition recommendations to improve care coordination and clinical outcomes. The system now works across multiple EHR platforms, including Veradigm EHR and Practice Fusion, supporting payer-provider collaboration and advancing value-based care initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) has announced the complete integration of advanced natural language processing (NLP) into its electronic health record (EHR) dataset. This enhancement allows for deeper clinical insights from unstructured EHR data, combined with structured data to create regulatory-grade, real-world data (RWD) for research purposes.

The Veradigm Network EHR Data is sourced from over 154 million unique patient records, making it one of the most comprehensive ambulatory databases in the United States. It encompasses over five billion distinct patient notes from multiple EHR systems and specialties, collected over a rolling five-year period.

Veradigm's NLP models, developed by clinicians and data scientists, extract important clinical insights into structured data tables. This integration offers researchers valuable insights into therapy decisions, disease progression, and patient outcomes, supporting clinical trials, regulatory submissions, and safety studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) has announced that over 300,000 healthcare providers across the United States are now using its automated medical chart retrieval solution, Veradigm eChart Courier. This milestone highlights the increasing demand for solutions that enhance efficiency, reduce administrative burdens, and facilitate seamless connections between healthcare providers and payers.

The eChart Courier solution automates the medical chart retrieval process, saving time, resources, and expenses for both providers and health plans. It securely delivers medical records via electronic transfer and presents clinical data to health plans in an easily analyzable format.

Tom Langan, Interim CEO, President and Chief Commercial Officer of Veradigm, emphasized the company's commitment to helping healthcare stakeholders control costs and optimize health outcomes through innovative tools like eChart Courier. Keri Straub of Clinix Center for Health praised the solution for improving efficiency, reducing paperwork, enhancing compliance with health plan requirements, and allowing clinical teams to focus more on patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
News
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX), a leading healthcare data and technology solutions provider, has been ranked as the top vendor for broad retrospective vendors in KLAS's Risk Adjustment 2024 report. The report highlighted the increasing demand for comprehensive risk adjustment solutions, including both retrospective and prospective capabilities.

Veradigm clients reported strong satisfaction with the company's suite of solutions, making it the most recommended vendor. Clients interviewed by KLAS noted significant outcomes, including increased ROI from retrospective risk adjustment solutions, more reliable submissions, and comprehensive validation processes.

Veradigm's risk adjustment solutions offer a full spectrum of services for health plans, supporting them in achieving operational goals and improving financial performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
Rhea-AI Summary

Veradigm Payerpath has been ranked the #1 overall vendor for end-to-end revenue cycle management (RCM) solutions by Black Book™ for the third consecutive year. This recognition highlights Veradigm's commitment to connecting providers, patients, and payers seamlessly.

Key features of Veradigm Payerpath include:

  • Maximizing and accelerating revenue
  • Streamlining communications with payers and patients
  • Boosting profitability for practices of all sizes and specialties
  • Upcoming ability to view and address open Gaps in Care from various payers
  • Practice management platform agnostic
  • Seamless interface with major systems

Veradigm Payerpath achieved top scores in several key performance indicators, including strategic alignment, innovation, integration, data security, and best of breed technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) announced positive impacts for orthopedic practices using its Coding Services. Key results in the first 12 months include:

  • Reducing surgical claims payment cycle by up to 5-10%
  • Increasing Relative Value Units (RVUs) by up to 3-5%

The service addresses challenges in complex surgical coding and staff shortages, helping practices improve revenue and documentation. Unity MSK, a multi-site orthopedic practice, reported significant results after implementing Veradigm Coding Services. The company's expertise in orthopedic-specific coding has helped Unity MSK combat increased denials and capture potential missing revenue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
none
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) announced that Black Book Research ranked Veradigm Payer Analytics as the top overall payer analytics solutions vendor for 2024. This recognition highlights Veradigm's achievements in client satisfaction, reliability, innovation, and technology. Veradigm Payer Analytics offers comprehensive insights for health plans to improve outcomes and reduce costs by providing a holistic view of healthcare data. The solution supports various functional areas such as Finance, Risk Adjustment, Quality, and Network Management. Interim CEO Tom Langan emphasized the value of Veradigm's solutions in enhancing financial performance and quality scores.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) announced that its Payerpath platform has been rated the top provider of claims and clearinghouse solutions for small medical practices by Black Book Research for the third consecutive year. Payerpath achieved high scores in 11 out of 18 key performance indicators (KPIs) for small practices and seven KPIs for larger medical groups. The platform interacts with over 60 practice management systems and 3000 payers, processing over 450 million claims annually with a clean claims rate exceeding 98%. Payerpath aims to reduce the administrative burden on healthcare staff while improving patient experience.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
News
Rhea-AI Summary

Veradigm announces key leadership updates effective June 7, 2024. Tom Langan, President and Chief Commercial Officer (CCO), will become the interim Chief Executive Officer (CEO). Langan has been part of Veradigm since 2018, with over 25 years in life sciences and analytics. Lee Westerfield, interim Chief Financial Officer (CFO), extends his term through December 31, 2024. Current interim CEO, Dr. Yin Ho, will step down. The company will not make permanent executive appointments during its strategic alternatives exploration. Executive Chairman Greg Garrison expressed confidence in Langan's leadership and appreciation for Westerfield's continued contributions. Dr. Ho's tenure included the acquisition of ScienceIO and advancements in AI, positioning Veradigm as a leader in healthcare data intelligence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.89%
Tags
none
Rhea-AI Summary

Veradigm, a healthcare data and technology provider, announced it is exploring strategic alternatives to maximize shareholder value, potentially including a sale, merger, or other transaction. The company emphasizes there is no assurance that any transaction will be completed. Veradigm plans to maintain focus on its core business, which it describes as strong and profitable.

The firm reaffirmed its 2024 guidance, projecting revenues between $620 million and $635 million and adjusted EBITDA between $104 million and $113 million. As of March 31, 2024, Veradigm held $343 million in cash and cash equivalents and $208 million in debt, resulting in net cash of $135 million. J.P. Morgan Securities is the financial advisor, and Sidley Austin LLP is the legal counsel.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.89%
Tags
none

FAQ

What is the current stock price of Veradigm (MDRX)?

The current stock price of Veradigm (MDRX) is $4.31 as of February 20, 2026.

What is the market cap of Veradigm (MDRX)?

The market cap of Veradigm (MDRX) is approximately 499.6M.

MDRX Rankings

MDRX Stock Data

499.56M
103.82M
Health Information Services
Healthcare
Link
United States
Chicago

MDRX RSS Feed